Oncimmune Holdings PLC
LSE:ONC
Intrinsic Value
Oncimmune Holdings Plc engages in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. [ Read More ]
The intrinsic value of one
ONC
stock under the Base Case scenario is
24.08
GBX.
Compared to the current market price of 23.5 GBX,
Oncimmune Holdings PLC
is
Undervalued by 2%.
Oncimmune Holdings PLC's market capitalization is 17.4m GBX.
ONC stock price is 23.5 GBX.
ONC stock price (23.5 GBX) is 2% less than its Intrinsic Value (24.08 GBX).
ONC. Open DCF Valuation
ONC.
ONC's long-term assets (8m GBP) exceed its long-term liabilties (8m GBP).
ONC has positive Net Debt. This means that the company has more debt (5m GBP) than cash and short-term investments (3m GBP).
ONC's Revenue has dropped by 50% over the past 12 months.
ONC's ROE (Return on Equity) has significantly increased in the last 3 years from -2 242% to -233%, and is approaching profitability.
ONC's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -103% to -68%, and is approaching profitability.
ONC has negative Operating Income for the last twelve months.
ONC has positive Net Income for the last twelve months.
ONC's ROE (Return on Equity) for the past 12 months is negative and is equal to -233%.
ONC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -68%.
ONC has positive Gross Profit for the last twelve months.
ONC has negative Free Cash Flow for the last twelve months.
ONC's short-term assets (6m GBP) exceed its short-term liabilties (1m GBP).
ONC has negative three-year average ROE (Return on Equity): -544%. The company is not efficient at transforming stockholders' equity into net income.
ONC has negative three-year average ROIC (Return on Invested Capital): -76%. The company is not efficient at using invested capital to generate operating income.
ONC's D/E (Debt to Equity) is very high and is equal to 7.56.
ONC's Altman Z-Score is very low and is equal to -7.
ONC doesn't generate enough operating income (-4m GBP) to safely cover interest payments on its debt (2m GBP).
Valuation Backtest
Oncimmune Holdings PLC
Run backtest to discover the historical profit from buying and selling
ONC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Oncimmune Holdings PLC
Balance Sheet Decomposition
Oncimmune Holdings PLC
| Current Assets | 5.6m |
| Cash & Short-Term Investments | 3.2m |
| Receivables | 2.1m |
| Other Current Assets | 235k |
| Non-Current Assets | 2.9m |
| PP&E | 591k |
| Intangibles | 2.1m |
| Other Non-Current Assets | 219k |
| Current Liabilities | 1.4m |
| Accounts Payable | 894k |
| Other Current Liabilities | 528k |
| Non-Current Liabilities | 6.4m |
| Long-Term Debt | 5m |
| Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
Oncimmune Holdings PLC
|
Revenue
|
1.2m
GBP
|
|
Cost of Revenue
|
-360k
GBP
|
|
Gross Profit
|
792k
GBP
|
|
Operating Expenses
|
-4.7m
GBP
|
|
Operating Income
|
-3.9m
GBP
|
|
Other Expenses
|
8m
GBP
|
|
Net Income
|
4.1m
GBP
|
Free Cash Flow Analysis
Oncimmune Holdings PLC
ONC Profitability Score
Profitability Due Diligence
Oncimmune Holdings PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Oncimmune Holdings PLC's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
ONC Solvency Score
Solvency Due Diligence
Oncimmune Holdings PLC's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Score
Oncimmune Holdings PLC's solvency score is 29/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ONC Price Targets Summary
Oncimmune Holdings PLC
Shareholder Return
ONC Price
Oncimmune Holdings PLC
| Average Annual Return | 58.95% |
| Standard Deviation of Annual Returns | 207.02% |
| Max Drawdown | -94% |
| Market Capitalization | 17.4m GBX |
| Shares Outstanding | 74 142 096 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Oncimmune Holdings PLC
Country
Industry
Market Cap
Dividend Yield
Description
Oncimmune Holdings Plc engages in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company is headquartered in Nottingham, Nottinghamshire and currently employs 52 full-time employees. The company went IPO on 2016-05-18. The firm operates through two segments: Early CDT Lung and ImmunoINSIGHTS. The Early CDT Lung segment is engaged in the production and sale of kits for the early detection of lung cancer via a blood test. The ImmunoINSIGHTS segment focuses on autoantibody profiling service. The ImmunoINSIGHTS is Company's service to the life science industry, built off its autoantibody profiling technology. Its technology can be utilized for profiling autoantibodies in patients receiving or about to receive treatment. Its Early cancer detection test (EarlyCDT) is a blood test that detects the elevated presence of autoantibodies generated by the body's immune system as a natural defense against cancer cells. The firm's immunodiagnostic test, EarlyCDT Lung, can detect and help identify lung cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one
ONC
stock under the Base Case scenario is
24.08
GBX.
Compared to the current market price of 23.5 GBX,
Oncimmune Holdings PLC
is
Undervalued by 2%.
You don't have any saved screeners yet
